Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself

Therapeutic inhibition of poly(ADP-ribose) polymerase (PARP), as monotherapy or to supplement the potencies of other agents, is a promising strategy in cancer treatment. We previously reported that the first PARP inhibitor to enter clinical trial, rucaparib (AG014699), induced vasodilation in vivo i...

Descripción completa

Detalles Bibliográficos
Autores principales: McCrudden, Cian M., O’Rourke, Martin G., Cherry, Kim E., Yuen, Hiu-Fung, O’Rourke, Declan, Babur, Muhammad, Telfer, Brian A., Thomas, Huw D., Keane, Patrick, Nambirajan, Thiagarajan, Hagan, Chris, O’Sullivan, Joe M., Shaw, Chris, Williams, Kaye J., Curtin, Nicola J., Hirst, David G., Robson, Tracy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331495/
https://www.ncbi.nlm.nih.gov/pubmed/25689628
http://dx.doi.org/10.1371/journal.pone.0118187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331495/
https://www.ncbi.nlm.nih.gov/pubmed/25689628
http://dx.doi.org/10.1371/journal.pone.0118187

Ejemplares similares